JP2003522732A5 - - Google Patents

Download PDF

Info

Publication number
JP2003522732A5
JP2003522732A5 JP2000589041A JP2000589041A JP2003522732A5 JP 2003522732 A5 JP2003522732 A5 JP 2003522732A5 JP 2000589041 A JP2000589041 A JP 2000589041A JP 2000589041 A JP2000589041 A JP 2000589041A JP 2003522732 A5 JP2003522732 A5 JP 2003522732A5
Authority
JP
Japan
Prior art keywords
endothelin antagonist
composition
poly
acetylglucosamine
glucosamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000589041A
Other languages
English (en)
Japanese (ja)
Other versions
JP4795539B2 (ja
JP2003522732A (ja
Filing date
Publication date
Priority claimed from US09/218,288 external-priority patent/US6063911A/en
Application filed filed Critical
Publication of JP2003522732A publication Critical patent/JP2003522732A/ja
Publication of JP2003522732A5 publication Critical patent/JP2003522732A5/ja
Application granted granted Critical
Publication of JP4795539B2 publication Critical patent/JP4795539B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000589041A 1998-12-22 1999-12-21 細胞増殖性疾患を治療するための方法および組成物 Expired - Lifetime JP4795539B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/218,288 US6063911A (en) 1993-12-01 1998-12-22 Methods and compositions for treatment of cell proliferative disorders
US09/218,288 1998-12-22
PCT/US1999/030575 WO2000036918A1 (en) 1998-12-22 1999-12-21 Methods and compositions for treatment of cell proliferative disorders

Publications (3)

Publication Number Publication Date
JP2003522732A JP2003522732A (ja) 2003-07-29
JP2003522732A5 true JP2003522732A5 (https=) 2007-02-08
JP4795539B2 JP4795539B2 (ja) 2011-10-19

Family

ID=22814511

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000589041A Expired - Lifetime JP4795539B2 (ja) 1998-12-22 1999-12-21 細胞増殖性疾患を治療するための方法および組成物

Country Status (14)

Country Link
US (1) US6063911A (https=)
EP (1) EP1139752B1 (https=)
JP (1) JP4795539B2 (https=)
CN (1) CN100488512C (https=)
AT (1) ATE294504T1 (https=)
AU (1) AU780248B2 (https=)
CA (1) CA2356087C (https=)
DE (1) DE69925156T2 (https=)
ES (1) ES2242448T3 (https=)
HK (1) HK1043507B (https=)
IL (2) IL143700A0 (https=)
NO (1) NO330033B1 (https=)
NZ (1) NZ512586A (https=)
WO (1) WO2000036918A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6743783B1 (en) * 1993-12-01 2004-06-01 Marine Polymer Technologies, Inc. Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine
US5858350A (en) * 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
US5977117A (en) 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
AP9901643A0 (en) 1997-04-28 1999-10-02 Texas Biotechnology Corp Sulfonamides for treatment of endothelin-mediated disorders.
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
US7566452B1 (en) * 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) * 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
HUP0203935A3 (en) 1999-12-31 2006-02-28 Encysive Pharmaceuticals Inc H Sulfonamides and derivatives thereof that modulate the activity of endothelin, pharmaceutical compositions containing them and their use
US20050245451A1 (en) * 2000-04-05 2005-11-03 Pincus Matthew R Peptides selectively lethal to malignant and transformed mammalian cells
TWI306760B (en) * 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
YU12703A (sh) * 2000-08-22 2006-05-25 Boehringer Ingelheim Pharma Gmbh. & Co.Kg. Farmaceutska kombinacija antagonista angiotenzina ii i inhibitora angiotenzin i konvertujućeg enzima
US7041657B2 (en) 2001-02-12 2006-05-09 Marine Polymer Technologies Inc. Compositions and methods for modulation of vascular structure and/or function
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
EP1587424A4 (en) 2002-12-31 2012-01-25 Marinepolymer Tech Inc Bleeding Compounds and their uses
EP1592430A4 (en) * 2003-01-17 2006-05-31 Threshold Pharmaceuticals Inc TREATMENT OF GOOD PROSTATE HYPERPLASIA BY MEANS OF ENERGYSTIC ACTIVE SUBSTANCES
NZ542501A (en) * 2003-02-24 2009-09-25 Marinepolymer Tech Inc Compositions comprising chitin or chitosan and use thereof
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
US8152750B2 (en) * 2003-09-12 2012-04-10 Marine Polymer Technologies, Inc. Vascular access preservation in hemodialysis patients
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
WO2006016904A2 (en) * 2004-04-14 2006-02-16 Uab Research Foundation Activators of hexosamine biosynthesis as inhibitors of injury induced by ischemia or hemorrhagic shock
EP3263581B2 (en) 2005-05-17 2025-07-09 University of Connecticut Compositions and methods for immunomodulation in an organism
EP2366787B1 (en) 2006-01-13 2019-12-11 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells
US8871247B2 (en) * 2007-02-19 2014-10-28 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
NZ582330A (en) 2007-06-27 2012-05-25 Marinepolymer Tech Inc COMPLEXES OF IL-15 AND IL-15Ra (RECEPTOR ALPHA) AND USES THEREOF
EP2224961A1 (en) * 2007-11-26 2010-09-08 The Research Foundation of the State University of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
WO2011020047A1 (en) 2009-08-14 2011-02-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of il-15 to increase thymic output and to treat lymphopenia
WO2011130646A1 (en) 2010-04-15 2011-10-20 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly -n-acetylglucosamine nanofibers
NZ732118A (en) 2011-04-15 2018-11-30 Marine Polymer Tech Inc Treatment of disease with poly-n-acetylglucosamine nanofibers
GB201616087D0 (en) * 2016-09-21 2016-11-02 Tomalgae Cvba Algae comprising therapeutic and/or nutritional agents
CA3096978A1 (en) 2018-04-06 2019-10-10 Oncolyze, Inc. Compositions for use in lysis of selective cancer cells

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1038367A (en) * 1963-05-28 1966-08-10 Beecham Group Ltd Penicillin derivatives
US3989535A (en) * 1974-02-11 1976-11-02 American Cyanamid Company Solution of poly(N-acetyl-D-glucosamine)
US3988411A (en) * 1974-02-11 1976-10-26 American Cyanamid Company Spinning and shaping poly-(N-acetyl-D-glucosamine)
JPS55152705A (en) * 1979-05-18 1980-11-28 Mitsubishi Rayon Co Ltd Preparation of water-soluble alkali chitin
US4378017A (en) * 1980-03-21 1983-03-29 Kureha Kagaku Kogyo Kabushiki Kaisha Composite material of de-N-acetylated chitin and fibrous collagen
JPS5927826A (ja) * 1982-08-10 1984-02-14 Masuko Suzuki 抗感染症剤
US4803168A (en) * 1983-09-01 1989-02-07 Damon Biotech, Inc. Microencapsulation with polymers
US4749620A (en) * 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
GR862353B (en) * 1985-09-23 1987-01-19 Lilly Co Eli Anti-tumor method and compounds
JPS62288602A (ja) * 1986-06-06 1987-12-15 Agency Of Ind Science & Technol キトサン変性物粒子の製造方法
US4942129A (en) * 1987-07-28 1990-07-17 Queen's University At Kingston Multiple membrane microencapsulation
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5008116A (en) * 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
US5071977A (en) * 1989-05-10 1991-12-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Plaque inhibiting oligosaccharide
US5116747A (en) * 1989-08-11 1992-05-26 University Of Waterloo Immobilization of biologically active material in capsules prepared from a water-soluble polymer and chitosan acetate
US5529914A (en) * 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
JPH04334322A (ja) * 1991-05-09 1992-11-20 Unitika Ltd 抗腫瘍剤
US5382569A (en) * 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
CA2072395A1 (en) * 1991-07-01 1993-01-02 John T. Hunt Bicyclic endothelin analogues
US5229123A (en) * 1991-10-09 1993-07-20 Hoffmann-La Roche Inc. Antifungal agents
US5219749A (en) * 1991-10-09 1993-06-15 Institute For Molecular Biology & Biotechnology/Forth Process for isolating and preparing purified chitin deacetylase
EP0610441A4 (en) * 1991-10-29 1996-01-10 Clover Cons Ltd CROSSLINKABLE POLYSACCHARIDES, POLYCATIONS AND LIPIDS CAN BE USED TO ENCODE AND DISPENSE MEDICINAL PRODUCTS.
UA44686C2 (uk) * 1991-11-05 2002-03-15 Смітклайн Бічем Корпорейшн Похідні індану або індену як антагоністи ендотелінових рецепторів, фармацевтична композиція на їх основі, спосіб їх одержання та спосіб пригнічення ендотелінових рецепторів
IL100096A (en) * 1991-11-20 1996-03-31 Univ Ramot Method for entrapment of active materials in chitosan
US5260002A (en) * 1991-12-23 1993-11-09 Vanderbilt University Method and apparatus for producing uniform polymeric spheres
US5573934A (en) * 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5550110A (en) * 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
WO1994003483A1 (en) * 1992-07-30 1994-02-17 Chiron Corporation Endothelin receptor-binding compounds
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
US5624679A (en) * 1993-12-01 1997-04-29 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine biological barriers
US5622834A (en) * 1993-12-01 1997-04-22 Marine Polymer Technologies, Inc. Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture
US5858350A (en) * 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
WO1996011927A1 (en) * 1994-10-12 1996-04-25 Abbott Laboratories Endothelin antagonists
TW313568B (https=) * 1994-12-20 1997-08-21 Hoffmann La Roche
US5658943A (en) * 1995-01-05 1997-08-19 Warner-Lambert Company Phenylalanine derivatives as endothelin antagonists
WO1996039122A1 (en) * 1995-06-06 1996-12-12 Marine Polymer Technologies, Inc. POLY-β-1→4-N-ACETYLGLUCOSAMINE
US5998468A (en) * 1995-08-24 1999-12-07 Warner-Lambert Company Furanone endothelin antagonists
US6043241A (en) * 1996-04-10 2000-03-28 Warner-Lambert Company Ketoacid endothelin antagonists

Similar Documents

Publication Publication Date Title
JP2003522732A5 (https=)
JP2610792B2 (ja) 多糖誘導体および薬物担体
US6063911A (en) Methods and compositions for treatment of cell proliferative disorders
JP2006502129A5 (https=)
BR0113663A (pt) Composições de pelìcula de pectina
EP0740650A4 (en) CO-MEDICINAL PRODUCTS USED AS A REGULATED MEDICINE DELIVERY PROCESS
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
AU3090295A (en) Wound healing agent
JP2006513992A5 (https=)
CA2321461A1 (en) Cross-linked high amylose starch having functional groups as a matrix for the slow release of pharmaceutical agents
WO2007070547A3 (en) Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
BR9502016A (pt) Derivado de propiofenona processo para a preparação do mesmo composição farmacêutica agente antidiabete e uso do dito derivado
Sarrazin et al. Heparan sulfate mimicry: a synthetic glycoconjugate that recognizes the heparin binding domain of interferon-γ inhibits the cytokine activity
CA2261597A1 (fr) Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant
BR0313239A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de doenças
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
EP2298336A3 (en) Promotion of epithelial regeneration
BR9808008A (pt) Processo para o tratamento anticoagulante e/ou antitrombótico de um ser humano ou outro paciente animal de sangue quente, usos de um oligossacarìdeo sulfatado e na fabricação de um medicamento, e, composição farmacêutica ou veterinária para tratamento anticoagulante e/ou antitrombótico.
UA99094C2 (ru) Способ лечения пациента с системной красной волчанкой
US20210393855A1 (en) New hydrogels having a silylated structure, and method for obtaining same
MXPA01009690A (es) Moduladores de polisacaridos y usos de los mismos.
ES2283585T3 (es) Amilopectina hiperramificada para su utloizacion en procedimientos para el tratamiento quirurgico o terapeutico de mamiferos o en procedimientos de diagnostico, especialmente para su uso como extensor del volumen de plasma.
Singh et al. Chitosan hydrogel: Its applications in medicine and dentistry
WO2002069961A8 (en) Il-8 receptor ligands-drugs for inflammatory and autoimmune diseases
WO2001008708A3 (en) Enhanced delivery via serpin enzyme complex receptor ligands